Robert F. Kennedy Jr. defended his prior public statements on a range of health policy issues in a fiery confirmation ...
Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced ...
Barclays analyst Peter Lawson maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a price target of ...
Fate Therapeutics, Inc. SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...
Given this risk, we thought we'd take a look at whether Fate Therapeutics (NASDAQ:FATE) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the ...
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback